🇺🇸 FDA
Patent

US 10335402

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

granted A61KA61K31/454A61P

Quick answer

US patent 10335402 (Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders) held by Takeda Pharmaceutical Company Limited expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/454, A61P, A61P1/00, A61P1/12